A recent study by Wang et al.(2016a) claims that the low-frequency variant NR1H3p.Arg415Gln is sufficient to cause multiple sclerosis in certain individuals and determines a patient's likelihood of primary progressive disease.
Our study indicates that pharmacological activation of LXRA or its targets may lead to effective treatments for the highly debilitating and currently untreatable progressive phase of MS.
We recently published a study proposing a rare variant in the NR1H3 gene (rs61731956" genes_norm="10062">p.R415Q, rs61731956) as responsible for the onset of multiple sclerosis (MS) in two multi-incident families (Wang et al., 2016).